SCHEMBL2883382

SCHEMBL2883382

CCCCCCCCCCCCCCCC(=O)OC(=O)c1cccnc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.67
L3MBTL1 Q9Y468 1/20 0.62
MAPT P10636 3/20 0.60
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60
POLB P06746 2/20 0.60
NPC1 O15118 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CYP1A2 P05177 1/20 0.56
CYP2C9 P11712 1/20 0.56
TSHR P16473 1/20 0.56
CYP2C19 P33261 1/20 0.56
ALDH1A1 P00352 3/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
HPGD P15428 1/20 0.56
HTT P42858 1/20 0.55
TBXAS1 P24557 4/20 0.54
HDAC3 O15379 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4624298 1.00 LMNA (0.67) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL23903383 1.00 LMNA (0.67) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL29001187 0.99 LMNA (0.65) LMNAL3MBTL1MAPTNFKB1NFKB2
Hydrochloric Acid SCHEMBL4271423 0.99 LMNA (0.65) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL23926881 0.99 LMNA (0.64) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL27623813 0.93 ALDH1A1 (0.56) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL5987475 0.93 LMNA (0.58) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL8213632 0.91 FAAH (0.57) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL23069546 0.88 L3MBTL1 (0.60) LMNAL3MBTL1MAPTNFKB1NFKB2
SCHEMBL27094819 0.86 CYP3A4 (0.50) LMNAL3MBTL1MAPTNFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120917-B1 Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy UNIV KENTUCKY RES FOUND (US) 2014-01-22 EP claimed
US-20100173957-A1 METHOD FOR ALLEVIATING SIDE EFFECTS OF RETINOIC ACID THERAPY AND/OR IMPROVING EFFICACY WITHOUT INTERFERING WITH EFFICACY NIADYNE, INC. 2010-07-08 US claimed
JP-2010520202-A 2010-06-10 JP claimed
EP-2120917-A2 METHOD FOR ALLEVIATING SIDE EFFECTS OF RETINOIC ACID THERAPY AND/OR IMPROVING EFFICACY WITHOUT INTERFERING WITH EFFICACY University Of Kentucky Research Foundation (US) 2009-11-25 EP claimed
WO-2008106177-A2 METHOD FOR ALLEVIATING SIDE EFFECTS OF RETINOIC ACID THERAPY AND/OR IMPROVING EFFICACY WITHOUT INTERFERING WITH EFFICACY UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2008-09-04 WO claimed
CN-120000544-A Use of compounds and compositions thereof for reducing muscle tone 上海克琴科技有限公司 2025-05-16 CN disclosed
CN-115400140-B Use of ribofuranosylpyridine derivatives for the prevention or treatment of epilepsy or convulsions 宁波熙健医药科技有限公司 2024-02-20 CN disclosed